Table 4.

Adjusted HRs (95% CIs) of atherosclerotic event and congestive heart failure hospitalization by levels of FGF-23 in sensitivity analyses

ModelEvents (n)aFGF-23
<96.0 RU/ml96.0–145.4 RU/ml145.5–238.9 RU/ml≥239.0 RU/mlContinuous per Doublingb
Atherosclerotic event
 Primary modelc261Reference1.32 (0.90 to 1.92)1.47 (1.14 to 1.90)1.76 (1.20 to 2.59)1.24 (1.09 to 1.40)
 Definite event215Reference1.22 (0.89 to 1.66)1.31 (0.98 to 1.76)1.42 (0.90 to 2.23)1.19 (1.01 to 1.41)
 Event or death468Reference1.28 (0.94 to 1.73)1.61 (1.34 to 1.93)2.36 (1.90 to 2.94)1.38 (1.30 to 1.46)
 Including post-ESRD events306Reference1.41 (0.90 to 2.22)1.58 (1.22 to 2.04)1.89 (1.28 to 2.80)1.24 (1.15 to 1.34)
 CHF as time-varying covariate261Reference1.31 (0.90 to 1.92)1.46 (1.13 to 1.89)1.74 (1.18 to 2.57)1.23 (1.08 to 1.39)
 Multiple imputation of missing covariates287Reference1.12 (0.84 to 1.49)1.26 (0.96 to 1.64)1.59 (1.17 to 2.15)1.21 (1.07 to 1.36)
Congestive heart failure hospitalization
 Primary modelc321Reference1.36 (0.78 to 2.38)1.74 (1.06 to 2.86)2.98 (1.97 to 4.52)1.45 (1.28 to 1.65)
 Definite event235Reference1.40 (0.65 to 3.01)1.85 (0.93 to 3.67)3.30 (1.75 to 6.21)1.50 (1.29 to 1.74)
 Event or death518Reference1.28 (1.07 to 1.53)1.70 (1.19 to 2.42)2.97 (2.59 to 3.40)1.49 (1.40 to 1.58)
 Including post-ESRD events342Reference1.49 (0.87 to 2.56)1.83 (1.12 to 2.99)2.88 (1.80 to 4.62)1.40 (1.23 to 1.60)
 ASCVD as time-varying covariate321Reference1.34 (0.76 to 2.36)1.72 (1.04 to 2.84)2.96 (1.95 to 4.48)1.45 (1.28 to 1.64)
 Multiple imputation of missing covariates360Reference1.17 (0.68 to 2.00)1.65 (1.03 to 2.65)2.73 (1.89 to 3.95)1.43 (1.30 to 1.58)
  • CHF, congestive heart failure; ASCVD, atherosclerotic cardiovascular disease.

  • a The number of events represents events in adjusted models and may be lower than the overall number of events in the study population because of model-wise deletion.

  • b Risk per 1-unit change in log2(FGF-23).

  • c Adjusted for age; sex; race/ethnicity; household income; eGFR; urine albumin-to-creatinine ratio; history of hypertension; hypercholesterolemia; history of atherosclerotic cardiovascular disease; history of congestive heart failure; diabetes; control of BP to <140/90 mmHg; hemoglobin A1c; smoking status; body mass index; waist circumference; serumtriglycerides; LDL cholesterol; use of antiplateletmedications, angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, β-blockers, statins, and loop diuretics; and the number of classes of BP medications used. Clustered by center.